MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-Pd-1

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.341
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma

New England Journal of Medicine
Medicine
2013English

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Can IDO Activity Predict Primary Resistance to Anti-Pd-1 Treatment in NSCLC?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2018English

Comprehensive Molecular and Clinical Characterization of Asian Melanoma Patients Treated With Anti-Pd-1 Antibody

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

MA11.06 Prognostic Value of Complement System in NSCLC and Its Association With PD-1 and PD-L1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA04.01 Cemiplimab, a Human Monoclonal Anti-Pd-1, Alone or in Combination With Radiotherapy: Phase 1 NSCLC Expansion Cohorts

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

022 Diet-Induced Obesity Predisposes Anti-Pd-1 Antibody-Treated Mice to Imiquimod-Mediated Psoriasiform Dermatitis: Implications for Immune-Related Adverse Events in Cancer Patients Treated With Anti-Pd-1

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

SCLE and Dermatomyositis in Anti‐PD‐1 Therapy

British Journal of Dermatology
DermatologyMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy